
ğŸ§¬ Hybrid Machine Learning Framework for Drug Efficacy Prediction in Breast Cancer

Authors: Sharon MelhiÂ¹, Dhanashree BhamareÂ²  
Â¹Amity University Bengaluru  
Â²Somaiya Vidyavihar University, Mumbai

ğŸ“Œ Overview

This project proposes a hybrid machine learning-based framework that predicts the LN_IC50 inhibitory concentration of cancer drugs to support personalized treatment strategies in breast cancer. By integrating pharmacogenomic, clinical, and molecular data, the model aims to assist in dose optimization, reduce empirical prescriptions, and foster explainability in precision oncology.

ğŸš€ Features include:
- ğŸ” Prediction using XGBoost and Deep Neural Networks
- ğŸ§  Ensemble learning for robust performance
- ğŸ§¾ SHAP analysis for interpretability
- ğŸ“Š Visual analytics to support clinical decisions

ğŸ—‚ï¸ Project Structure

- `model5.py`: Complete pipeline (data loading âœ preprocessing âœ training âœ evaluation âœ visualization)
- `Abstract.docx`: Detailed research abstract
- Output plots:
  - ğŸ“ˆ `ln_ic50_by_cancer.png`
  - ğŸ“‰ `ln_ic50_vs_auc.png`
  - ğŸ§ª `ln_ic50_by_stage.png`
  - ğŸ§  `shap_importance.png`

ğŸ§° Requirements

Install the necessary packages with:

```bash
pip install pandas numpy scikit-learn xgboost tensorflow shap matplotlib seaborn openpyxl
````

ğŸ—ƒï¸ Data Sources

* Pharmacogenomics: `GDSC2_fitted_dose_response_27Oct23.xlsx`
* Clinical Data: `clinical.tsv` (TCGA-BRCA subset)

ğŸ—‚ï¸ Place these in the `data/` directory as specified in the code.

â–¶ï¸ Running the Project

```bash
python model5.py
```

ğŸ“Š Output Highlights

* âœ… RMSE: \~0.21
* âœ… RÂ² Score: \~0.89
* ğŸ” Cross-Validated RMSE: Printed in console

Key Insights ğŸ§ 

* Drug resistance differs by subtype
* Higher dose needed in Stage IV (\~10% more)
* Key predictors: AUC, tumor stage, patient age

ğŸ”® Future Enhancements

* Real-time patient data integration
* Cross-cancer type application
* Web dashboard for clinicians

ğŸ™ Acknowledgements

Thanks to GDSC and TCGA for datasets
